All Updates

All Updates

icon
Filter
Partnerships
Insilico Medicine and Fosun Pharma team up for multi-target AI drug development
AI Drug Discovery
Jan 11, 2022
This week:
Partnerships
Intuitive AI partner with Moda Center to implement Oscar Sort recycling technology
Waste Recovery & Management Tech
Yesterday
Management news
Funding
Minze Health raises USD 5.3 million in funding for product and market expansion; appoints new VP
Preventive Healthcare
Yesterday
Partnerships
Firefly Aerospace partners with True Anomaly for Space Force rapid-response mission launches
Space Travel and Exploration Tech
Yesterday
Funding
zkPass raises USD 12.5 million in Series A funding
Enterprise Blockchain Solutions
Yesterday
Partnerships
Ontada partners with Microsoft to process unstructured oncology data using Azure AI
Clinical Trial Technology
Yesterday
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
AI Drug Discovery

AI Drug Discovery

Jan 11, 2022

Insilico Medicine and Fosun Pharma team up for multi-target AI drug development

Partnerships

  • Hong Kong-based AI drug discovery company Insilico Medicine has collaborated with Chinese pharmaceutical company Fosun Pharma to develop novel therapeutics across multiple areas.

  • Both parties will work on four biological targets by leveraging Insilico’s AI platforms as well as Fosun’s drug development and commercialization expertise. The duo will also develop Insilico’s Glutaminyl-peptide cyclotransferase like (QPCTL) program, where Insilico will be responsible for the preclinical development of a candidate and advancing it to the investigational new drug (IND) stage, while Fosun will be in charge of its clinical testing and development.

  • Through the partnership, Fosun will also advance its internal drug development programs using Insilico's PandaOmics and Chemistry42 platforms.

  • Insilico will receive an upfront payment of USD 13 million, followed by additional milestones and a share of commercialization profits. Fosun Pharma will also make an equity investment in Insilico.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.